Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Piccini, JP; Stevens, SR; Chang, Y; Singer, DE; Lokhnygina, Y; Go, AS; Patel, MR; Mahaffey, KW; Halperin, JL; Breithardt, G; Hankey, GJ; Hacke, W; Becker, RC; Nessel, CC; Fox, KAA; Califf, RM; ROCKET AF Steering Committee and Investigators,

Published Date

  • September 10, 2013

Published In

Volume / Issue

  • 128 / 11

Start / End Page

  • e172 - e173

PubMed ID

  • 24019452

Electronic International Standard Serial Number (EISSN)

  • 1524-4539

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.113.004013


  • eng

Conference Location

  • United States